Obesity drugs are a modern day gold rush for drugmakers. Eli Lilly , valued at $347 billion, is close behind $207 billion Novo Nordisk in releasing a weight loss drug, in a market expected to be worth …
Read Full Story at source (may require registration)
Latest posts by Gold Editor (see all)
- The new global gold rush - February 3, 2023
- Gold posts lowest finish in more than 3 weeks after a stronger than-expected U.S. jobs report - February 3, 2023
- Gold Weekly Price Forecast – Gold Markets Get Slammed - February 3, 2023